Ombitasvir/Paritaprevir/Ritonavir has 8 known drug interactions based on U.S. FDA drug labeling data. Of these, 8 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol, Ethynodiol Diacetate And Ethinyl Estradiol, Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate. Patients taking Ombitasvir/Paritaprevir/Ritonavir should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Contraindicated
- 8
Contraindicated (8)
- Ombitasvir/Paritaprevir/Ritonavir + Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol— Co-administration is contraindicated due to potential for ALT elevations.
- Ombitasvir/Paritaprevir/Ritonavir + Ethynodiol Diacetate And Ethinyl Estradiol— Do not co-administer due to potential for ALT elevations.
- Ombitasvir/Paritaprevir/Ritonavir + Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate— Do not co-administer due to potential for ALT elevations.
- Ombitasvir/Paritaprevir/Ritonavir + Levonorgestrel/Ethinyl Estradiol And Ethinyl Estradiol— Do not co-administer due to potential for ALT elevations.
- Ombitasvir/Paritaprevir/Ritonavir + Norethindrone Acetate, Ethinyl Estradiol And Ferrous Fumarate— Do not co-administer due to potential for ALT elevations.
- Ombitasvir/Paritaprevir/Ritonavir + Norethindrone Acetate/Ethinyl Estradiol— Coadministration is contraindicated due to potential for ALT elevations and risk of liver enzyme elevation.
- Ombitasvir/Paritaprevir/Ritonavir + Norethindrone And Ethinyl Estradiol— Do not co-administer with norethindrone and ethinyl estradiol due to potential for ALT elevations and risk of liver enzy…
- Ombitasvir/Paritaprevir/Ritonavir + Norgestrel And Ethinyl Estradiol— Do not co-administer due to potential for ALT elevations and liver enzyme elevation risk.